Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor

समान संसाधन

• Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors
  द्वारा: Niwakawa, Masashi, और अन्य
  प्रकाशित: (2013)
• Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
  द्वारा: Steeghs, Neeltje, और अन्य
  प्रकाशित: (2009)
• Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
  द्वारा: Rodenburg, RJ, और अन्य
  प्रकाशित: (2019)
• Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
  द्वारा: Bhargava, Pankaj, और अन्य
  प्रकाशित: (2011)
• The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation
  द्वारा: Lolkema, Martijn P., और अन्य
  प्रकाशित: (2015)